CKD BURDEN

THE IMPACT OF CHRONIC KIDNEY DISEASE ON PATIENTS WITH TYPE 2 DIABETES IS FAR-REACHING

Worldwide T2D Prevalence

As of 2019, approximately 463 million adults ages 20–79 have diabetes worldwide, of which around 90% have T2D1

40 percent T2D development

Up to 40% of patients with type 2 diabetes develop chronic kidney disease2

CKD death

Patients with stage 3 CKD are 10x more likely to die from any cause (including CV disease) than to progress to stage 5 CKD, dialysis, or kidney transplantation3*

CKD shortens life by 16 years

CKD can shorten life expectancy of patients with diabetes by up to 16 years, relative to the general population with neither disease4

*A Norwegian 10-year observational study of patients with CKD stage 3 (N=3047).3

Risk of CV events appears early in the course of CKD in patients with T2D and grows with disease severity.5

COMPARED WITH T2D ALONE, COMORBID KIDNEY DISEASE INCREASES CV MORTALITY6

CKD and T2D increase 10-year CV mortality chart

CKD PROGRESSION CAN HAVE SERIOUS CONSEQUENCES FOR PATIENTS

Dialysis and Kidney Transplant

CKD progression in T2D follows a path toward declining kidney function, CV decline, and ultimately end-stage renal disease. Once renal function declines below a certain threshold, patients face the complications and risks associated with ESRD.7,8

60 percent will not survive

Despite the standard treatments for ESRD (transplant or dialysis), once patients reach ESRD, approximately 60% will die in the next 5 years. Organ shortages might result in limited transplantation. Even in the best-case scenario, dialysis care or transplantation will result in much less than a naturally functioning kidney, which is why protecting the kidney from CKD progression is of primary importance.7,9,10

Current standard of care leaves patients open to the risks of inflammation and fibrosis, a largely unaddressed driver of CKD progression2,11-16
Read on

CKD: chronic kidney disease; CV: cardiovascular; ESRD: end-stage renal disease; T2D: type 2 diabetes.

References:

  • International Diabetes Federation. IDF Diabetes Atlas. 9th ed. Brussels; 2019. Accessed January 12, 2021. Available at: https://www.diabetesatlas.org. Return to content
  • Alicic RZ, et al. Clin J Am Soc Nephrol. 2017;12(12):2032–2045. Return to content
  • Eriksen BO, et al. Kidney Int. 2006;69(2):375–382. Return to content
  • Wen CP, et al. Kidney Int. 2017;92(2):388–396. Return to content
  • Amod A, et al; DEVOTE Study Group. Diabetes Ther. 2020;11(1):53–70. Return to content
  • Afkarian M, et al. J Am Soc Nephrol. 2013;24(2):302–308. Return to content
  • Thomas MC, et al. Nat Rev Dis Primers. 2015;1. doi:10.1038/nrdp.2015.18. Return to content
  • Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. Kidney Int Suppl. 2013;3(1):1–150. Return to content
  • Breyer MD, et al. Nat Rev Drug Discov. 2016;15(8):568–588. doi:10.1038/nrd.2016.67. Return to content
  • Pálsson R, et al. Adv Chronic Kidney Dis. 2014;21(3):273–280. Return to content
  • Cosentino F, et al; ESC Scientific Document Group. Eur Heart J. 2020;41(2):255–323. Return to content
  • Toth-Manikowski S, et al. J Diabetes Res. 2015;2015. doi:10.1155/2015/697010. Return to content
  • Alicic RZ, et al. Adv Chronic Kidney Dis. 2018;25(2):181–191. Return to content
  • Black LM, et al. J Histochem Cytochem. 2019;67(9):663–681. Return to content
  • Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. Kidney Int. 2020;98(4S):S1–S115. Return to content
  • Tuttle KR, et al. Am J Kidney Dis. 2021;77(1):94–109. Return to content

Follow:

© 2022 Bayer AG

Last updated on 04/25/22

This website is intended to provide information to an international audience of healthcare professionals outside the USA and UK.

  • PP-FINE-ALL-0140-1
Alt tag Alt tag